Literature DB >> 21914716

The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol.

Simon Shorvon1, Monica Ferlisi.   

Abstract

Super-refractory status epilepticus is defined as status epilepticus that continues or recurs 24 h or more after the onset of anaesthetic therapy, including those cases where status epilepticus recurs on the reduction or withdrawal of anaesthesia. It is an uncommon but important clinical problem with high mortality and morbidity rates. This article reviews the treatment approaches. There are no controlled or randomized studies, and so therapy has to be based on clinical reports and opinion. The published world literature on the following treatments was critically evaluated: anaesthetic agents, anti-epileptic drugs, magnesium infusion, pyridoxine, steroids and immunotherapy, ketogenic diet, hypothermia, emergency resective neurosurgery and multiple subpial transection, transcranial magnetic stimulation, vagal nerve stimulation, deep brain stimulation, electroconvulsive therapy, drainage of the cerebrospinal fluid and other older drug therapies. The importance of treating the identifying cause is stressed. A protocol and flowchart for managing super-refractory status epilepticus is suggested. In view of the small number of published reports, there is an urgent need for the establishment of a database of outcomes of individual therapies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21914716     DOI: 10.1093/brain/awr215

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  113 in total

1.  Pediatric super-refractory status epilepticus treated with allopregnanolone.

Authors:  Eileen Broomall; JoAnne E Natale; Michele Grimason; Joshua Goldstein; Craig M Smith; Celia Chang; Stephen Kanes; Michael A Rogawski; Mark S Wainwright
Journal:  Ann Neurol       Date:  2014-11-11       Impact factor: 10.422

2.  The blood-brain barrier hypothesis in drug resistant epilepsy.

Authors:  Nicola Marchi; Tiziana Granata; Andreas Alexopoulos; Damir Janigro
Journal:  Brain       Date:  2012-01-16       Impact factor: 13.501

Review 3.  Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.

Authors:  Annamaria Vezzani; Raymond Dingledine; Andrea O Rossetti
Journal:  Expert Rev Neurother       Date:  2015       Impact factor: 4.618

4.  Treatment of super-refractory status epilepticus: the sooner the better with less adverse effects.

Authors:  Jeffrey Buchhalter
Journal:  Epilepsy Curr       Date:  2013-09       Impact factor: 7.500

5.  Intravenous Corticosteroids as an Adjunctive Treatment for Refractory and Super-Refractory Status Epilepticus: An Observational Cohort Study.

Authors:  Vasiliki Pantazou; Jan Novy; Andrea O Rossetti
Journal:  CNS Drugs       Date:  2019-02       Impact factor: 5.749

Review 6.  Refractory and super-refractory status epilepticus--an update.

Authors:  Sara Hocker; William O Tatum; Suzette LaRoche; W David Freeman
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

Review 7.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 8.  Stiripentol in the Management of Epilepsy.

Authors:  Katherine C Nickels; Elaine C Wirrell
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

9.  Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study.

Authors:  Raoul Sutter; Stephan Marsch; Stephan Rüegg
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

Review 10.  Blood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approaches.

Authors:  Nicola Marchi; Tiziana Granata; Chaitali Ghosh; Damir Janigro
Journal:  Epilepsia       Date:  2012-08-20       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.